Option Investor
Newsletter

Bonus Play!

HAVING TROUBLE PRINTING?
Printer friendly version

CTIC - Cell Therapeutics $9.12

Cell Therapeutics (NASDAQ:CTIC) develops and commercializes a

range of novel treatments for cancer. The company's research

and in-licensing activities are concentrated on identifying new,

less toxic and more effective ways to treat cancer. The firm

markets TRISENOX for the treatment of relapsed or refractory

acute promyelocytic leukemia in the United States and in the

European Union. In addition, the company has a large number

of clinical development trials and/or investigator-sponsored

research trials related to potential market expansion for that

product. CTI is also developing XYOTAX for the treatment of

non-small cell lung cancer and ovarian cancer, and pixantrone,

for the treatment of non-Hodgkin's lymphoma.


This stock emerged a number of times during our technical
scans for bullish issues and despite the somewhat speculative
nature of the company's activities, we decided to list it for
the benefit of those readers who focus primarily on chart
patterns. The big move on Friday is likely due to comments
by WR Hambrecht, which noted that "CTIC could double or
more in the next 2-3 months" due to data from a Phase III
trial. The upside potential is also enhanced by a relatively
large short position in the issue, and that would certainly
explain the heavy volume associated with each upward spike
during the past few months. Speculation Only!

Fundamentals: http://finance.yahoo.com/q/ks?s=CTIC&quicken=2

Chart: http://finance.yahoo.com/q/bc?s=CTIC&t=6m

Sell Put FEB 7.50 CUC-NU
Current Bid = $0.20 Open Interest = 1442
Potential Profit (5 contracts) = $100
Return on Investment (max) = 10.1%
Cost Basis in Stock = $7.30
Days to Expiration = 27

Option Writers Newsletter Archives